# Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)

> **NCT01345240** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 705 (actual)

## Conditions studied

- Malaria
- Malaria Vaccines

## Interventions

- **BIOLOGICAL:** GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
- **BIOLOGICAL:** Engerix-B™ vaccine
- **BIOLOGICAL:** Infanrix/Hib™ vaccine
- **BIOLOGICAL:** Polio Sabin™ vaccine
- **BIOLOGICAL:** Rotarix™ vaccine
- **BIOLOGICAL:** Synflorix™ vaccine
- **BIOLOGICAL:** Measles vaccine
- **BIOLOGICAL:** Yellow fever vaccine

## Key facts

- **NCT ID:** NCT01345240
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-17
- **Primary completion:** 2013-01-09
- **Final completion:** 2017-02-09
- **Target enrollment:** 705 (ACTUAL)
- **Last updated:** 2019-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01345240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01345240, "Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01345240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*